All News
EULAR 2022 Featured Industry Abstracts
Below is a collection of several EULAR 2022 abstracts highlighted in recent press releases from companies sponsoring major clinical trials. You can search the EULAR site for these abstract and others here.
Read Article
Recommendations – Good & Bad (5.27.2022)
Dr. Jack Cush reviews the news, regulatory updates and journal reports from the past week on RheumNow.com. This week gout worries, mortality risks, measuring anti-drug antibodies and a better way in lupus?
Read Article
Can SGLT2 Inhibitors Be Protective in Lupus and Vasculitis?
SGLT2 inhibitors are all the buzz in the renal world with reports of a renal protective and mortality lowering effects. Maybe these agents should be considered and studied in lupus nephritis and ANCA- associated vasculitis.
Read Article
Relevance of Raynaud’s in Systemic Sclerosis
Raynaud’s phenomenon (RP) is integral to the diagnosis and management of systemic sclerosis (SSc) patients; a recent analysis suggests that RP should be characterized based on color change and the presence of other symptoms to know whether RP portends more serious manifestations.
Read Article
#POS0186 #EULAR2022 AURORA2 (Extension of original RCT to 2 years) showed:
💠#lupus nephritis patients on voclosporin maintained meaningful low uPCR and stability of eGFR at 2yrs
💠No unexpected safety signals
@RheumNow https://t.co/lnohgW7BsK
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Sustained benefits #voclosporin in #LupusNephritis AURORA2 - 2 year study POS0186:
👉no unexpected AEs; rate of AEs⬇️over time
👉COVID19 seen in 12 controls, 7 VCS
👉4 deaths w/control arm vs 0 deaths w/ VCS
👉GFR & sCr & reduction in UPCR remained stable #EULAR2022 @rheumnow
TheDaoIndex KDAO2011 ( View Tweet)
Can SGLT2 Inhibitors Be Protective in Lupus and Vasculitis?
SGLT2 inhibitors are all the buzz in the renal world with reports of a renal protective and mortality lowering effects
https://t.co/b7YupKPJr7
#MedEd https://t.co/AYPeX360Gv
Links:
Dr. John Cush RheumNow ( View Tweet)
Watch: Lupus Nephritis: The Blind Men and the Kidney with Dr. Joan Merrill
Joan Merrill discusses treatment of lupus nephritis. This was previously recorded at RheumNow Live 2022.
https://t.co/9GRw5VGTKr https://t.co/PS6aEk1fsx
Links:
Dr. John Cush RheumNow ( View Tweet)
Dr. Jack Cush reviews the news, regulatory updates and journal reports from the past week on https://t.co/V10S4oVFsv. This week gout worries, mortality risks, measuring anti-drug antibodies and a better way in lupus?
https://t.co/iaMQZtzdLm https://t.co/Zu9VwKoCAc
Dr. John Cush RheumNow ( View Tweet)
Looking forward to reading/watching the coverage of #EULAR2022 by our outstanding faculty, including Drs., Rachel Tate @uptoTate, Kathryn Dao @KDAO2011,
Robert Chao @doctorRBC , Janet Pope @Janetbirdope and Antoni Chan @synovialjoints . https://t.co/oBQCxzdzfF
Dr. John Cush RheumNow ( View Tweet)
Watch: Novel Treatment of SLE
Dr. Sonali Narain discusses new insights on existing treatments and newly approved therapy and soon to be approved therapies for SLE. #MedEd
https://t.co/7Op3R8IzV1
#MedEdTwitter https://t.co/qBMTbOBmyM
Links:
Dr. John Cush RheumNow ( View Tweet)
To TDM or Not in Rheumatology?
Therapeutic Drug Monitoring (TDM), especially for biologic therapies, has become a standard in gastroenterology, but shunned by most rheumatologists. But now, EULAR has a recommendation...
https://t.co/u86Vd8bFGr
#MedEdTwitter https://t.co/IpKqPoWM9R
Links:
Dr. John Cush RheumNow ( View Tweet)
Can SGLT2 Inhibitors Be Protective in Lupus and Vasculitis?
SGLT2 inhibitors are all the buzz in the renal world with reports of a renal protective and mortality lowering effects
https://t.co/9mzE06K9uO
#MedEd https://t.co/dVgOtCSHFU
Links:
Dr. John Cush RheumNow ( View Tweet)
86 #SLE pts w/ pulmonary embolism (age 38 yrs; avg lupus duration 46.5 mos) found 20% died; 1 yr (83.4%) & 3-year survival (79.4%). Mortality Predictors = Thrombocytopenia & lymphocytopenia. HCQ & anticoagulation were protective https://t.co/ot7H6LeLmu https://t.co/WdPgvOF8jJ
Links:
Dr. John Cush RheumNow ( View Tweet)
It's our 8th year covering this important meeting! Join us June 1 - 4 for key opinion leader perspectives, clinical trial highlights and more, as we cover #EULAR2022. https://t.co/eHziBN3TWk
Dr. John Cush RheumNow ( View Tweet)
Watch: Lupus Nephritis: The Blind Men and the Kidney with Dr. Joan Merrill
Joan Merrill discusses treatment of lupus nephritis. This was previously recorded at RheumNow Live 2022.
https://t.co/IDjOT3Acs0 https://t.co/HkYcoRx5P4
Links:
Dr. John Cush RheumNow ( View Tweet)
Rising Incidence of Systemic Lupus Erythematosus
Data from Olmstead county, MN over the past four decades shows that the incidence and prevalence of systemic lupus erythematosus (SLE) is increasing.
https://t.co/GUakRwwWQw https://t.co/LPnVMTT8Ro
Links:
Dr. John Cush RheumNow ( View Tweet)
Ontario population study shows that musculoskeletal disorders account for 12.3% of all adult emergency dept. visits and 28.5% outpatient physician visits https://t.co/Sq9n7RkIYK https://t.co/lKtQqR5Ja3
Links:
Dr. John Cush RheumNow ( View Tweet)
Watch: The Almighty ANA
Dr. Lipsky discussed how our thinking and use of ANA and serologic testing has evolved and is crucial to outcomes and trials in his lecture, The Almighty ANA, presented during the at #RNL2022 in March. #lupus
https://t.co/Xxxj18badY https://t.co/5pwV4xSGDx
Links:
Dr. John Cush RheumNow ( View Tweet)
Watch: Pregnancy Paradox: How Stopping Drugs Leads to Greater Harm
Uma Mahadevan, MD talks about the pregnancy paradox and how stopping medications in pregnancy to protect the fetus can actually lead to greater harm.
https://t.co/HYO5BdjwzZ https://t.co/IGeZ3O8Dno
Links:
Dr. John Cush RheumNow ( View Tweet)
